Rhythm METabolic, Inc.
Rhythm METabolic, Inc. is listed today as Rhythm Pharmaceuticals, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2017 | $20 M | No. 2 | $10 to $50 million | equity | SEC | |
| Aug 2015 | $40 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Rhythm Pharmaceuticals, Inc., its revenue in fiscal 2025 came from these business segments: Single reportable segment $189.76 million (100%).
Annual report (SEC XBRL) · Dec 2025
Rhythm METabolic, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2017).
SEC Form D · Jan 2017
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jan 2017
Products and services#
No products or services of Rhythm METabolic, Inc. are on record.
Investors#
24 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Baker Bros. Advisors (GP) LLC | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Baker Bros. Advisors LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| David P. Meeker | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2017) | SEC Form 3 |
| Deerfield Management Company, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Deerfield Mgmt III, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Deerfield Mgmt L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Deerfield Private Design Fund III, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Deerfield Special Situations Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Hadley Harbor Master Investors (Cayman) L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Ipsen, S.A. | Company | not stated | not stated | Held Series A and A-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Keith Michael Gottesdiener | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2017) | SEC Form 3 |
| MPM Asset Management Investors BV5 LLC | Fund or asset manager | not stated | not stated | Held Series A and A-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| MPM Bioventures V GP LLC | Venture capital | not stated | not stated | Held Series A and A-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| MPM Bioventures V LLC | Venture capital | not stated | not stated | Held Series A and A-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| MPM Bioventures V, L.P. | Venture capital | not stated | not stated | Held Series A and A-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| NEA 13 GP, Ltd | Company | not stated | not stated | Held Series A and A-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| NEA Partners 13, Limited Partnership | Fund or asset manager | not stated | not stated | Held Series A and A-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| New Enterprise Associates 13 LP | Fund or asset manager | not stated | not stated | Held Series A and A-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| OrbiMed Capital GP V LLC | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Pfizer Inc | Fund or asset manager | not stated | not stated | Held Series A and A-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Third Rock Ventures GP, L.P. | Venture capital | not stated | not stated | Held Series A and A-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Third Rock Ventures LP | Venture capital | not stated | not stated | Held Series A and A-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| TRV GP, LLC | Other | not stated | not stated | Held Series A and A-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 14 investors.
Largest shareholders today
Institutions holding Rhythm Pharmaceuticals, Inc. shares, as of Sep 30, 2026.
- Ra Capital Management, L.P.$635 M9.62%
- BlackRock, Inc.$569 M8.62%
- Baker Bros. Advisors LP$534 M8.08%
- Jpmorgan Chase & Co$339 M5.13%
- Vanguard Portfolio Management LLC$300 M4.54%
- Primecap Management Co/ca/$292 M4.42%
- Vanguard Capital Management LLC$286 M4.33%
- State Street Corp$251 M3.81%
- Perceptive Advisors LLC$241 M3.65%
- Westfield Capital Management Co LP$236 M3.58%
- Price T Rowe Associates Inc /MD/$222 M3.37%
- Goldman Sachs Group Inc$202 M3.05%
- Federated Hermes, Inc.$179 M2.71%
- Polar Capital Holdings Plc$158 M2.39%
- Capital Research Global Investors$152 M2.30%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Bart T. Henderson | Mr. Henderson is the President and Treasurer of the Issuer. | Jan 2017 |
| Keith Gottesdiener | Mr. Gottesdiener is the Chief Executive Officer of the Issuer. | Jan 2017 |
| Christophe Jean | Director | Jan 2017 |
| David J. McGirr | Director | Jan 2017 |
| David P. Meeker, M.D. | Director | Jan 2017 |
| Edward T. Mathers | Director | Jan 2017 |
| Jonathan T. Silverstein | Director | Jan 2017 |
| Keith Gottesdiener | Mr. Gottesdiener is the Chief Executive Officer of the Issuer. | Jan 2017 |
| Neil Exter | Director | Jan 2017 |
| Todd T. Foley | Director | Jan 2017 |
| Jean Christophe | Director | Aug 2015 |
| Bart T. Henderson | Mr. Henderson is the President and Treasurer of the Issuer. | Jan 2017 |
| Keith Gottesdiener | Mr. Gottesdiener is the Chief Executive Officer of the Issuer. | Jan 2017 |
About
Company in Boston, United States.
Went public since 2017. Its SEC number is that of a company listed on a stock exchange.